Literature DB >> 30135474

Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis.

Lin He1, Xinhua Liu1,2,3, Jianguo Yang1, Wanjin Li1, Shumeng Liu2, Xujun Liu1, Ziran Yang1, Jie Ren1, Yue Wang2, Lin Shan2, Chengjian Guan4, Fei Pei5, Liandi Lei6, Yu Zhang1, Xia Yi1, Xiaohan Yang1, Jing Liang1, Rong Liu4, Luyang Sun7, Yongfeng Shang8,9,10.   

Abstract

Hyperactivation of EGFR/PI3K/AKT is a prominent feature of various human cancers. Thus, understanding how this molecular cascade is balanced is of great importance. We report here that the ubiquitin-specific protease USP43 is physically associated with the chromatin remodeling NuRD complex and catalyzes H2BK120 deubiquitination. Functionally this coordinates the NuRD complex to repress a cohort of genes, including EGFR, which are critically involved in cell proliferation and carcinogenesis. We show that USP43 strongly suppresses the growth and metastasis of breast cancer in vivo. Interestingly, USP43 also exists in the cytoplasm, where it is phosphorylated by AKT, enabling its binding to the 14-3-3β/ε heterodimer and sequestration in the cytoplasm. Significantly, hyperactivation of EGFR/PI3K/AKT in breast cancer is associated with the cytoplasmic retention of USP43 and thus, the inhibition of its transcriptional regulatory function. Moreover, cancer-associated mutations of USP43 affect its subcellular localization and/or epigenetic regulatory functions. Nuclear USP43 is significantly reduced in breast carcinomas and is associated with EGFR accumulation and AKT hyperactivation. A low level of nuclear USP43 correlates with higher histologic grades and poor prognosis. Our study identifies USP43 to be an H2BK120 deubiquitinase and a potential tumor suppressor and reveals a reciprocally inhibitory loop between USP43 and EGFR/PI3K/AKT, whose imbalance drives breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30135474      PMCID: PMC6123467          DOI: 10.1038/s41422-018-0079-6

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  59 in total

1.  A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing.

Authors:  Yue Zhao; Guillaume Lang; Saya Ito; Jacques Bonnet; Eric Metzger; Shun Sawatsubashi; Eriko Suzuki; Xavier Le Guezennec; Hendrik G Stunnenberg; Aleksey Krasnov; Sofia G Georgieva; Roland Schüle; Ken-Ichi Takeyama; Shigeaki Kato; László Tora; Didier Devys
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

2.  The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.

Authors:  Y Zhang; G LeRoy; H P Seelig; W S Lane; D Reinberg
Journal:  Cell       Date:  1998-10-16       Impact factor: 41.582

Review 3.  PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.

Authors:  Angel Guerrero-Zotano; Ingrid A Mayer; Carlos L Arteaga
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

4.  Constitutively active phosphatidylinositol 3-kinase and AKT are sufficient to stimulate the epithelial Na+/H+ exchanger 3.

Authors:  W Lee-Kwon; D C Johns; B Cha; M Cavet; J Park; P Tsichlis; M Donowitz
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

5.  MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.

Authors:  Naoyuki Fujita; David L Jaye; Masahiro Kajita; Cissy Geigerman; Carlos S Moreno; Paul A Wade
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

6.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

Authors:  M Sun; G Wang; J E Paciga; R I Feldman; Z Q Yuan; X L Ma; S A Shelley; R Jove; P N Tsichlis; S V Nicosia; J Q Cheng
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

8.  Defining the human deubiquitinating enzyme interaction landscape.

Authors:  Mathew E Sowa; Eric J Bennett; Steven P Gygi; J Wade Harper
Journal:  Cell       Date:  2009-07-16       Impact factor: 41.582

Review 9.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

10.  14-3-3 proteins associate with phosphorylated simple epithelial keratins during cell cycle progression and act as a solubility cofactor.

Authors:  J Liao; M B Omary
Journal:  J Cell Biol       Date:  1996-04       Impact factor: 10.539

View more
  18 in total

1.  miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling.

Authors:  Xingzhou Yan; Pinghua Yang; Hu Liu; Yongyang Zhao; Zhixiong Wu; Baohua Zhang
Journal:  Cell Cycle       Date:  2022-02-23       Impact factor: 5.173

2.  MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR/PI3K/AKT Signaling Pathway.

Authors:  Shengya Cao; Longfei Li; Jia Li; Hongying Zhao
Journal:  Onco Targets Ther       Date:  2020-07-30       Impact factor: 4.147

Review 3.  Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Authors:  Chen-Xi Zhao; Chen-Ming Zeng; Ke Wang; Qiao-Jun He; Bo Yang; Fan-Fan Zhou; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

4.  Ubiquitination Destabilizes Protein Sphingosine Kinase 2 to Regulate Glioma Malignancy.

Authors:  Hongliang Wang; Bing Zhao; Erbao Bian; Gang Zong; Jie He; Yuyang Wang; Chunchun Ma; Jinghai Wan
Journal:  Front Cell Neurosci       Date:  2021-07-07       Impact factor: 5.505

Review 5.  Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer.

Authors:  Lucile M-P Jeusset; Kirk J McManus
Journal:  Cells       Date:  2019-02-16       Impact factor: 6.600

6.  LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.

Authors:  Hong Zhang; Yao-Zhen Pan; May Cheung; Mary Cao; Chao Yu; Ling Chen; Lei Zhan; Zhi-Wei He; Cheng-Yi Sun
Journal:  Cell Death Dis       Date:  2019-03-08       Impact factor: 8.469

7.  ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling.

Authors:  Chengjian Guan; Lin He; Zhenyu Chang; Xinjin Gu; Jing Liang; Rong Liu
Journal:  Oncogene       Date:  2019-10-28       Impact factor: 9.867

8.  USP11 acts as a histone deubiquitinase functioning in chromatin reorganization during DNA repair.

Authors:  Xia Ting; Lu Xia; Jianguo Yang; Lin He; Wenzhe Si; Yongfeng Shang; Luyang Sun
Journal:  Nucleic Acids Res       Date:  2019-10-10       Impact factor: 16.971

9.  USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2.

Authors:  Ning Dou; Qingqing Hu; Li Li; Qiong Wu; Yandong Li; Yong Gao
Journal:  Int J Biol Sci       Date:  2020-03-12       Impact factor: 6.580

10.  Global crotonylome reveals CDYL-regulated RPA1 crotonylation in homologous recombination-mediated DNA repair.

Authors:  Huajing Yu; Chen Bu; Yuncheng Liu; Tianyu Gong; Xiaoping Liu; Shumeng Liu; Xiaojun Peng; Wenting Zhang; Yani Peng; Jianguo Yang; Lin He; Yu Zhang; Xia Yi; Xiaohan Yang; Luyang Sun; Yongfeng Shang; Zhongyi Cheng; Jing Liang
Journal:  Sci Adv       Date:  2020-03-13       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.